 HOUSTON, April 29, 2021 PRNewswire -- Soliton, Inc., Nasdaq: SOLY Soliton or the Company, a medical device company with a novel and proprietary platform technology, today announced the U.S. Food and Drug Administration FDA clearance of the Companys special 510k for modifications to its RESONICTM device. We were thrilled to receive this clearance as it marks the last significant hurdle to our ability to initiate our commercial launch of the improved RESONIC device in the second quarter, stated Brad Hauser, Soliton CEO and President. 